AD
Elite in Dengue Fever
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Anna P. Durbin's experience treating your condition:
About Dr. Anna P. Durbin

Anna Durbin is an Infectious Disease expert in Baltimore, Maryland. Durbin has been practicing medicine for over 36 years and is rated as an Elite expert by MediFind in the treatment of Dengue Fever. She is also highly rated in 13 other conditions, according to our data. Her top areas of expertise are Dengue Fever, Viral Hemorrhagic Fever, Arbovirosis, and West Nile Virus Infection. She is licensed to treat patients in Maryland. Durbin is currently accepting new patients.

Her clinical research consists of co-authoring 146 peer reviewed articles and participating in 32 clinical trials in the past 15 years. In particular, she has co-authored 59 articles and participated in 25 clinical trials in the study of Dengue Fever.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Anna P. Durbin it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Call to see if your plan is accepted.
Locations
1800 Orleans St, Baltimore, MD 21287
Background & Education
Graduate Institution
Wayne State University School Of Medicine, 1987
Specialties
Infectious Disease
Licenses
Internal Medicine in MD
Hospital Affiliations
The Johns Hopkins Hospital
Howard County General Hospital
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


32 Clinical Trials

Phase I Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)
Phase I Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults
Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge
Evaluation of the Clinical and Immune Response Generated by Heterologous Attenuated Dengue Virus Infection
A Phase 1 Evaluation of the Safety and Immunogenicity of a Booster Dose of TV003 Administered 12 Months After Initial Vaccination With TV003
A Phase 1 Evaluation of the Safety and Immunogenicity of rDEN2Δ30-7169, a Live Attenuated Monovalent Dengue Virus Vaccine
Safety and Immunogenicity of a 2-Dose Regimen of rDEN2/4Δ30 Dengue Vaccine With Boosting at 4 Versus 6 Months
Phase 1 Study of the Safety and Immunogenicity of rDEN3/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3
Evaluation of the Safety and Immunogenicity of Heterologous Dengue Vaccine Administration in Dengue Immune Individuals
Safety and Immunogenicity of a 2-Dose Regimen of rDEN1delta30 Dengue Serotype 1 Vaccine With Boosting at 4 Versus 6 Months
Phase I Study of the Safety and Immunogenicity of rDEN1delta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 1
View 30 Less Clinical Trials -

146 Total Publications

Dengue: A Growing Problem With New Interventions.


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
Advanced
Advanced
Advanced